346 related articles for article (PubMed ID: 33850327)
1. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
3. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
4. Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
[TBL] [Abstract][Full Text] [Related]
5. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
Du P; Geng J; Wang F; Chen X; Huang Z; Wang Y
Int J Med Sci; 2021; 18(6):1356-1362. PubMed ID: 33628091
[TBL] [Abstract][Full Text] [Related]
6. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
[TBL] [Abstract][Full Text] [Related]
7. The shortcomings of tocilizumab in COVID-19.
Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
[TBL] [Abstract][Full Text] [Related]
8. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Smetana K; Brábek J
In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
[TBL] [Abstract][Full Text] [Related]
9. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
10. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
11. Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.
Janssen MTHF; Ramiro S; Landewé RBM; Magro-Checa C; Mostard RLM
Ann Rheum Dis; 2021 Oct; 80(10):1362-1363. PubMed ID: 33958327
[No Abstract] [Full Text] [Related]
12. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.
Ringer M; Azmy V; Kaman K; Tang D; Cheung H; Azar MM; Price C; Malinis M
Transpl Infect Dis; 2021 Apr; 23(2):e13556. PubMed ID: 33378571
[TBL] [Abstract][Full Text] [Related]
13. In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor.
Ando T; Yamamoto M; Takamori Y; Tsukamoto K; Fuji D; Kawakami T
Biosci Biotechnol Biochem; 2021 Apr; 85(5):1170-1174. PubMed ID: 33590853
[TBL] [Abstract][Full Text] [Related]
14. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
16. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Corominas H; Castellví I; Diaz-Torné C; Matas L; de la Rosa D; Mangues MA; Moya P; Pomar V; Benito N; Moga E; Sosa NH; Casademont J; Domingo P
Medicine (Baltimore); 2021 May; 100(19):e25923. PubMed ID: 34106658
[TBL] [Abstract][Full Text] [Related]
17. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
Ali A; Kamjani MH; Kesselman MM
Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
19. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
Khaedir Y; Kartika R
J Interferon Cytokine Res; 2021 Feb; 41(2):37-43. PubMed ID: 33621130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]